A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications

Volumn 6, Issue , 2014, Pages 179-187

  Frost, Charles ^a   Song, Yan ^a   Barrett, Yu Chen ^a   Wang, Jessie ^b   Pursley, Janice ^c   Boyd, Rebecca A ^d   LaCreta, Frank ^a  

^a Translational Research   (United States)

^b Bristol Myers Squibb   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

Author keywords

Apixaban; Pharmacodynamics; Pharmacokinetics; Rivaroxaban; Safety

Indexed keywords

APIXABAN; RIVAROXABAN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONTUSION; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; EVENING DOSAGE; FEMALE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; PAIN; PARESTHESIA; PHARMACODYNAMICS; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; STEADY STATE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84924811736     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S61131     Document Type: Article

References (27)

1. Xarelto® (rivaroxaban) [prescribing information]. Leverkusen, Germany: Bayer Healthcare AG; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf. Accessed February 6, 2013.
2. Eliquis® (apixaban) tablets [prescribing information]. New York: Bristol-Myers Squibb Company; 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf. Accessed January 24, 2013.
3. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2): 476–487.
4. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013;51(7):549–561.
5. Xarelto® (rivaroxaban). Summary of product characteristics. Leverkusen, Germany: Bayer Pharma AG. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed May 24, 2012.
6. Eliquis® (apixaban) tablets. Summary of product characteristics. New York: Bristol-Myers Squibb Pfizer EEIG. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed June 2, 2013.
7. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharma­codynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776–786.
8. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873–880.
9. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory mea­surement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–1271.
10. Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6): 908–916.
11. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549–558.
12. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100(3):453–461.
13. Cui Y, Song Y, Wang J, et al. Single-and multiple-dose pharmacoki­netics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol. 2013;5:177–184.
14. Yamahira N, Frost C, Fukase H, et al. Safety, tolerability, pharma­cokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther. 2014;52(7): 564–573.
15. Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Quantification of apixaban’s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010;88(3):375–382.
16. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5(12):2368–2375.
17. Eriksson BI, Borris LC, Dahl OE, et al; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114(22):2374–2381.
18. Eriksson BI, Borris L, Dahl OE, et al; ODIXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4(1):121–128.
19. Turpie AG, Fisher WD, Bauer KA, et al; OdiXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3(11):2479–2486.
20. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivar­oxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007;120(5):685–693.
21. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775.
22. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594–604.
23. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632): 31–39.
24. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786.
25. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for throm­boprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807–815.
26. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for throm­boprophylaxis after hip replacement. N Engl J Med. 2010;363(26): 2487–2498.
27. Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676): 1673–1680.